Characterization and Preclinical Evaluation of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Chronic Lymphocytic Leukemia

被引：0
|
作者：
Tantawy, Shady I. [1 ]
Timofeeva, Natalia [1 ]
Fujiwara, Hitomi [2 ]
Hatakeyama, Mariko [2 ]
Herrera, Breana [1 ]
Loza, Lizbeth [1 ]
Asami, Tokiko [2 ]
Ohmoto, Hiroshi [2 ]
Miyamoto, Kyoko [3 ]
Nishioka, Yu [2 ]
Arimura, Akinori [3 ]
Sawa, Masaaki [2 ]
Jain, Nitin [4 ]
Gandhi, Varsha [1 ,4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[2] Carna Biosci Inc, Kobe, Hyogo, Japan
[3] CarnaBio USA Inc, San Francisco, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189659
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Preclinical testing of a novel CDK9 inhibitor in chronic lymphocytic leukemia
    Imsak, R.
    Goethert, J. R.
    Moellmann, M.
    Duehrsen, U.
    Eickhoff, J.
    Baumann, M.
    Unger, A.
    Schulz-Fademrecht, C.
    Duerig, J.
    ONKOLOGIE, 2011, 34 : 195 - 196
  • [22] Preclinical Testing Of a Novel Axl-Kinase Inhibitor In Chronic Lymphocytic Leukemia
    Goebel, Maria
    Moellmann, Michael
    Goergens, Andre
    Duehrsen, Ulrich
    Goethert, Joachim Rudolf
    Giebel, Bernd
    Schultz-Fademrecht, Carsten
    Unger, Anke
    Klebl, Bert
    Choidas, Axel
    Duerig, Jan
    BLOOD, 2013, 122 (21)
  • [23] Preclinical evaluation of a selective inhibitor of the ABL tyrosine kinase as a therapeutic agent for chronic myelogenous leukemia
    Druker, BJ
    Tamura, S
    Buchdunger, E
    Ohno, S
    Bagby, GC
    Lydon, NB
    BLOOD, 1995, 86 (10) : 2392 - 2392
  • [24] The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
    Herman, Sarah E. M.
    Montraveta, Arnau
    Niemann, Carsten U.
    Mora-Jensen, Helena
    Gulrajani, Michael
    Krantz, Fanny
    Mantel, Rose
    Smith, Lisa L.
    McClanahan, Fabienne
    Harrington, Bonnie K.
    Colomer, Dolors
    Covey, Todd
    Byrd, John C.
    Izumi, Raquel
    Kaptein, Allard
    Ulrich, Roger
    Johnson, Amy J.
    Lannutti, Brian J.
    Wiestner, Adrian
    Woyach, Jennifer A.
    CLINICAL CANCER RESEARCH, 2017, 23 (11) : 2831 - 2841
  • [25] Preclinical evaluation of mosunetuzumab for the treatment of relapsed/refractory chronic lymphocytic leukemia
    Barrett, Kathy
    Lu, Kai
    Jin, Hyun Yong
    Millen, Rosie
    Lefebure, Marcus
    Jiang, Yanwen
    CANCER RESEARCH, 2023, 83 (07)
  • [26] Harnessing the Fcμ Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia
    Vire, Berengere
    Skarzynski, Martin
    Thomas, Joshua D.
    Nelson, Christopher G.
    David, Alexandre
    Aue, Georg
    Burke, Terrence R., Jr.
    Rader, Christoph
    Wiestner, Adrian
    CANCER RESEARCH, 2014, 74 (24) : 7510 - 7520
  • [27] Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation
    Walsh, Shawn P.
    Shahripour, Aurash
    Tang, Haifeng
    Teumelsan, Nardos
    Frie, Jessica
    Zhu, Yuping
    Priest, Birgit T.
    Swensen, Andrew M.
    Liu, Jessica
    Margulis, Michael
    Visconti, Richard
    Weinglass, Adam
    Felix, John P.
    Brochu, Richard M.
    Bailey, Timothy
    Thomas-Fowlkes, Brande
    Alonso-Galicia, Magdalena
    Zhou, Xiaoyan
    Pai, Lee-Yuh
    Corona, Aaron
    Hampton, Caryn
    Hernandez, Melba
    Bentley, Ross
    Chen, Jing
    Shah, Kashmira
    Metzger, Joseph
    Forrest, Michael
    Owens, Karen
    Tong, Vincent
    Ha, Sookhee
    Roy, Sophie
    Kaczorowski, Gregory J.
    Yang, Lihu
    Parmee, Emma
    Garcia, Maria L.
    Sullivan, Kathleen
    Pasternak, Alexander
    ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (07): : 747 - 752
  • [28] Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
    Balog, Aaron
    Lin, Tai-An
    Maley, Derrick
    Gullo-Brown, Johnni
    Kandoussi, Enzo Hamza
    Zeng, Jianing
    Hunt, John T.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (03) : 467 - 476
  • [29] Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis
    Hopkins, Brian T.
    Bame, Eris
    Bajrami, Bekim
    Black, Cheryl
    Bohnert, Tonika
    Boiselle, Carrie
    Burdette, Doug
    Burns, Jeremy C.
    Delva, Luisette
    Donaldson, Douglas
    Grater, Richard
    Gu, Chungang
    Hoemberger, Marc
    Johnson, Josh
    Kapadnis, Sudarshan
    King, Kris
    Lulla, Mukesh
    Ma, Bin
    Marx, Isaac
    Magee, Tom
    Meissner, Robert
    Metrick, Claire M.
    Mingueneau, Michael
    Murugan, Paramasivam
    Otipoby, Kevin L.
    Polack, Evelyne
    Poreci, Urjana
    Prince, Robin
    Roach, Allie M.
    Rowbottom, Chris
    Santoro, Joseph C.
    Schroeder, Patricia
    Tang, Hao
    Tien, Eric
    Zhang, Fengmei
    Lyssikatos, Joseph
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (02) : 1206 - 1224
  • [30] Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).
    Chang, Betty Y.
    Furman, Richard R.
    Zapatka, Marc
    Barrientos, Jacqueline Claudia
    Li, Daniel
    Steggerda, Susanne
    Eckert, Karl
    Francesco, Michelle
    Woyach, Jennifer Ann
    Johnson, Amy J.
    James, Danelle Frances
    Versele, Matthias
    Byrd, John C.
    Stilgenbauer, Stephan
    Buggy, Joseph J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345